Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

Gordon Rees was employed at at ICI North Tees Works as a general maintenance assistant between 1986 and 1990 ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity. The oncologists examined deveral pivotal trials ...

CLEVELAND, March 10, 2026 /PRNewswire/ -- Oncologists currently have limited tools to predict which lung cancer patients will benefit from immunotherapy. The publication of a multi-institutional study ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...